natgillin/translations-raw huggingface dataset:
Co-administration with REYATAZ/ritonavir may result in increased concentrations of salmeterol and an increase in salmeterolassociated adverse events.
Pri sočasni uporabi zdravila REYATAZ/ritonavirja se koncentracije salmeterola lahko povečajo in s tem se poveča tudi pojavnost neželenih učinkov salmeterola.
Co-administration of REYATAZ and elbasvir/grazoprevir is contraindicated because of a significant increase in grazoprevir plasma concentrations and an associated potential increase in the risk of ALT elevations (see section 4.3).
Sočasna uporaba zdravila REYATAZ in elbasvirja/grazoprevirja je kontraindicirana zaradi pričakovanega povečanja koncentracij grazoprevirja v plazmi in s tem povezanega možnega večjega tveganja za zvišanje vrednosti ALT (glejte poglavje 4.3).
REYATAZ 300 mg hard capsules
REYATAZ 300 mg trde kapsule
The decrease in AUC, Cmax, and Cmin was not mitigated when an increased dose of REYATAZ/ritonavir (400/100 mg once daily) was temporally separated from omeprazole by 12 hours.
Če so povečan odmerek zdravila REYATAZ/ritonavirja (400/100 mg enkrat na dan) začasno ločili od uporabe omeprazola za 12 ur, se zmanjšanje vrednosti AUC, Cmax, in Cmin ni ublažilo.
Nevirapine 200 mg twice daily (atazanavir 400 mg once daily with ritonavir 100 mg once daily)
Nevirapin 200 mg dvakrat na dan (atazanavir 400 mg enkrat na dan z ritonavirjem 100 mg enkrat na dan)
INFORMATION IN BRAILLE Outer carton: REYATAZ 50 mg
PODATKI V BRAILLOVI PISAVI Škatla: REYATAZ 50 mg
Your doctor will evaluate how severe your liver disease is before deciding whether you can take REYATAZ if you are taking any of these medicines: see also Other medicines and REYATAZ rifampicin (an antibiotic used to treat tuberculosis) astemizole or terfenadine (commonly used to treat allergy symptoms, these medicines may be available without prescription); cisapride (used to treat gastric reflux, sometimes called heartburn); pimozide (used to treat schizophrenia); quinidine or bepridil (used to correct heart rhythm); ergotamine, dihydroergotamine, ergonovine, methylergonovine (used to treat headaches); and alfuzosin (used to treat enlarged prostatic gland) quetiapine (used to treat schizophrenia, bipolar disorder and major depressive disorder); lurasidone (used to treat schizophrenia) medicines containing St. John's wort (Hypericum perforatum, a herbal preparation)
če jemljete katero od naslednjih zdravil: glejte tudi Druga zdravila in zdravilo REYATAZ rifampicin (antibiotik, s katerim zdravimo tuberkulozo), astemizol ali terfenadin (z njima zdravimo simptome alergije in ju ponekod dobimo brez recepta); cisaprid (zdravilo za zdravljenje refluksa želodčne vsebine ali zgage); pimozid (zdravilo za zdravljenje shizofrenije); kinidin ali bepridil (zdravili za uravnavanje srčnega ritma); ergotamin, dihidroergotamin, ergonovin, metilergonovin (zdravila za zdravljenje glavobolov); alfuzosin (uporabljamo ga za zdravljenje povečane prostate), kvetiapin (uporabljamo ga za zdravljenje shizofrenije, bipolarne motnje in velike depresije); lurasidon (uporabljamo ga za zdravljenje shizofrenije), pripravki, ki vsebujejo šentjanževko (Hypericum perforatum, zdravilo rastlinskega izvora),
a The mean baseline CD4 cell count was 337 cells/mm3 (range: 14 to 1,543 cells/mm3) and the mean baseline plasma HIV-1 RNA level was 4.4 log10 copies/ml (range: 2.6 to 5.88 log10 copies/ml).
a Srednje število celic CD4 v izhodišču je bilo 337 celic/mm3 (razpon od 14 do 1.543 celic/mm3), srednja vrednost plazemske HIV-1 RNA v izhodišču pa 4,4 log10 kopij/ml (razpon od 2,6 do 5,88 log10 kopij/ml).
If the co-administration of REYATAZ with an NNRTI is required, an increase in the dose of both REYATAZ and ritonavir to 400 mg and 200 mg, respectively, in combination with efavirenz could be considered with close clinical monitoring.
Če je potrebno sočasno zdravljenje z zdravilom REYATAZ in z nenukleozidnim zaviralcem reverzne transkriptaze (NNRTI; “non-nucleoside reverse transcriptase inhibitor”), je v primeru sočasne uporabe efavirenza treba razmisliti o povečanju odmerka zdravila REYATAZ do 400 mg in povečanju odmerka ritonavirja do 200 mg, pri čemer je potreben skrben klinični nadzor.
Opaque blue and powder blue capsule printed with white and blue inks, with "BMS 150 mg" on one half and with "3624" on the other half.
Neprozorna modra in praškasto modra kapsula, ki ima na eni polovici odtisnjeno oznako "BMS 150 mg", na drugi pa "3624".
Co-administration of REYATAZ/ritonavir with proton pump inhibitors is not recommended.
Sočasne uporabe zdravila REYATAZ/ritonavirja in zaviralcev protonske črpalke ne priporočamo.
INFORMATION IN BRAILLE Outer carton: REYATAZ 300 mg
PODATKI V BRAILLOVI PISAVI Škatla: REYATAZ 300 mg
Rifabutin 150 mg twice weekly (atazanavir 300 mg and ritonavir 100 mg once daily)
Rifabutin 150 mg dvakrat na teden (atazanavir 300 mg in ritonavir 100 mg enkrat na dan)
Fluconazole 200 mg once daily (atazanavir 300 mg and ritonavir 100 mg once daily)
Flukonazol 200 mg enkrat na dan (atazanavir 300 mg in ritonavir 100 mg enkrat na dan)
Co-administration of REYATAZ with glecaprevir/pibrentasvir fixed dose combination is contraindicated because of the potential increase in the risk of ALT elevations due to a significant increase in glecapreir and pibrentasvir plasma concentrations (see section 4.3).
Sočasna uporaba zdravila REYATAZ in fiksne kombinacije glecaprevir/pibrentasvir je kontraindicirana zaradi možnega večjega tveganja za zvišanje vrednosti ALT, povezanega s pomembnim povečanjem koncentracij glaceprevirja in pibrentasvirja v plazmi (glejte poglavje 4.3).
Opaque red and blue capsule printed with white ink, with "BMS 300 mg" on one half and with "3622" on the other half.
Neprozorna rdeča in modra kapsula, ki ima na eni strani odtisnjeno oznako "BMS 300 mg", na drugi pa "3622".
The mechanism of interaction is CYP3A4 inhibition by atazanavir/ritonavir.
Mehanizem interakcije je zaviranje CYP3A4 z atazanavirjem/ritonavirjem.
Geometric mean (CV%)
AUC ng•h/ml geometrična sredina (KV%)
Opaque blue and white capsule printed with white and blue inks, with "BMS 100 mg" on one half and with "3623" on the other half.
Neprozorna modra in bela kapsula, ki ima na eni polovici odtisnjeno oznako "BMS 100 mg", na drugi pa "3623".
In HIV-infected patients with atazanavir/ritonavir at an increased dose of 400/100 mg once daily
Pri z virusom HIV okuženih bolnikih, ki so se zdravili z atazanavirjem/ritonavirjem v zvišanem odmerku 400/100 mg enkrat na dan Famotidin 20 mg dvakrat na dan
Co-administration of quetiapine with REYATAZ is contraindicated as REYATAZ may increase quetiapine-related toxicity.
Sočasna uporaba kvetiapina z zdravilom REYATAZ je kontraindicirana, saj lahko zdravilo REYATAZ okrepi toksične učinke kvetiapina.
Instructions for REYATAZ oral powder:
Navodila za uporabo zdravila REYATAZ peroralni prašek:
REYATAZ 150 mg hard capsules atazanavir
REYATAZ 150 mg trde kapsule atazanavir
REYATAZ 200 mg hard capsules
REYATAZ 200 mg trde kapsule
The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with H2blockers.
Mehanizem interakcije je zmanjšana topnost atazanavirja zaradi zvišane vrednosti pH želodčnega soka, ki je posledica uporabe antagonista histaminskih receptorjev H2.
The mechanism of diltiazem/atazanavir interaction is CYP3A4 inhibition.
Mehanizem interakcije diltiazem/atazanavir je inhibicija CYP3A4.
Have the child drink the mixture.
Otrok naj zaužije tudi to mešanico.
Each carton contains one high-density polyethylene (HDPE) bottle closed with child-resistant polypropylene closure.
Ena škatla vsebuje eno plastenko iz polietilena visoke gostote.
Co-administration of salmeterol and REYATAZ is not recommended (see section 4.5).
Sočasna uporaba salmeterola in zdravila REYATAZ ni priporočljiva (glejte poglavje 4.5).
80 mgc at least 35
80 mg c najmanj 35
other medicines to treat HIV infection (e.g. indinavir, nevirapine and efavirenz) boceprevir and sofosbuvir/velpatasvir/voxilaprevir (used to treat hepatitis C) sildenafil, vardenafil, or tadalafil (used by men to treat impotence (erectile dysfunction)) if you are taking an oral contraceptive ("the Pill") with REYATAZ to prevent pregnancy, be sure to take it exactly as instructed by your doctor and not miss any doses any medicines used to treat diseases related to the acid in the stomach (e.g. antacids to be taken 1 hour before taking REYATAZ or 2 hours after taking REYATAZ, H2-blockers like famotidine and proton pump inhibitors like omeprazole) medicines to lower blood pressure, to slow heart rate, or to correct heart rhythm (amiodarone, diltiazem, systemic lidocaine, verapamil) atorvastatin, pravastatin, and fluvastatin (used to lower blood cholesterol) salmeterol (used to treat asthma) cyclosporin, tacrolimus, and sirolimus (medicines to decrease the effects of body's immune system) certain antibiotics (rifabutin, clarithromycin) ketoconazole, itraconazole, and voriconazole (antifungals) warfarin (anticoagulant, used to reduce the blood clots) carbamazepine, phenytoin, phenobarbital, lamotrigine (antiepileptics) irinotecan (used to treat cancer) sedative agents (e.g. midazolam administered by injection) buprenorphine (used to treat opioid addiction and pain).
vsa zdravila, ki jih uporabljamo za zdravljenje bolezni, povezanih z želodčno kislino (npr. antacidi, ki jih je treba jemati 1 uro pred zdravilom REYATAZ ali 2 uri po zdravilu REYATAZ, antagonisti histaminskih receptorjev H2, kot je famotidin, in zaviralci protonske črpalke, kot je omeprazol), zdravila za znižanje zvišanega krvnega tlaka, za upočasnitev srčnega utripa ali za uravnavanje srčnega ritma (amiodaron, diltiazem, sistemski lidokain, verapamil), atorvastatin, pravastatin in fluvastatin (zdravila za zniževanje holesterola v krvi), salmeterol (zdravilo za zdravljenje astme), ciklosporin, takrolimus in sirolimus (zdravila, ki zavirajo imunski sistem), nekateri antibiotiki (rifabutin, klaritromicin), ketokonazol, itrakonazol in vorikonazol (antimikotiki), varfarin (antikoagulant za preprečevanje krvnih strdkov), karbamazepin, fenitoin, fenobarbital in lamotrigin (antiepileptiki), irinotekan (zdravilo za zdravljenje raka), pomirjevala (npr. midazolam, ki ga uporabljamo v obliki injekcij), buprenorfin (uporabljamo ga za zdravljenje zasvojenosti z opioidi in lajšanje bolečine).
Each capsule contains 200 mg of atazanavir (as sulphate).
Ena kapsula vsebuje 200 mg atazanavirja (v obliki sulfata).
REYATAZ 300 mg hard capsules are also supplied in blister strips in packs of 30 capsules.
REYATAZ 300 mg trde kapsule so na voljo tudi v pretisnih omotih s 30 kapsulami.
Do not use an infant bottle to give REYATAZ mixed with infant formula.
Pri dajanju zdravila REYATAZ pomešanega z začetno formulo za dojenčke ne smete uporabiti stekleničke za hranjenje dojenčkov.
Proton pump inhibitors Omeprazole 40 mg once daily (atazanavir 400 mg once daily with ritonavir 100 mg once daily)
Zaviralci protonske črpalke Omeprazol 40 mg enkrat na dan (atazanavir 400 mg enkrat na dan z ritonavirjem 100 mg enkrat na dan)
uncommon: nephrolithiasisa, haematuria, proteinuria, pollakiuria, interstitial nephritis, chronic kidney diseasea; rare: kidney pain
občasni: nefrolitiazaa, hematurija, proteinurija, polakisurija, intersticijski nefritis, kronična ledvična bolezena; redki: bolečina v ledvicah
Fill a small container with the sachets' content.
Vsebino vrečic stresite v manjšo posodico.
INFORMATION IN BRAILLE Outer carton: REYATAZ 100 mg
PODATKI V BRAILLOVI PISAVI Škatla: REYATAZ 100 mg
Co-administration with REYATAZ may result in increased concentrations of salmeterol and an increase in salmeterol-associated adverse events.
Pri sočasni uporabi zdravila REYATAZ se koncentracije salmeterola lahko povečajo in s tem se poveča tudi pojavnost neželenih učinkov salmeterola.
Serum concentrations of verapamil may be increased by REYATAZ/ritonavir due to CYP3A4 inhibition.
Pri sočasni uporabi z zdravilom REYATAZ/ritonavirjem se lahko serumske koncentracije verapamila povečajo zaradi inhibicije CYP3A4.
The co-administration of REYATAZ/ritonavir with stavudine is not expected to significantly alter the exposure of stavudine.
Pri sočasni uporabi zdravila REYATAZ/ritonavirja s stavudinom pomembnejših sprememb v izpostavljenosti stavudinu ni pričakovati.
REYATAZ 150 mg hard capsules are also supplied in blister strips in packs of 60 capsules.
REYATAZ 150 mg trde kapsule so na voljo tudi v pretisnih omotih s 60 kapsulami.
NAME OF THE MEDICINAL PRODUCT REYATAZ 150 mg hard capsules atazanavir
IME ZDRAVILA REYATAZ 150 mg trde kapsule atazanavir
common: jaundice; uncommon: hepatitis, cholelithiasisa, cholestasisa; rare: hepatosplenomegaly, cholecystitisa
pogosti: zlatenica; občasni: vnetje jeter, holelitiazaa, holestazaa; redki: povečanje jeter in vranice, vnetje žolčnikaa
No dosage adjustment is necessary if methadone is coadministered with REYATAZ.
Pri sočasni uporabi metadona z zdravilom REYATAZ odmerkov ni treba prilagajati.
REYATAZ 300 mg hard capsules are supplied in bottles of 30 capsules.
REYATAZ 300 mg trde kapsule so na voljo v plastenkah s 30 kapsulami.
Co-administration with medicinal products that are substrates of the CYP3A4 isoform of cytochrome P450 and have narrow therapeutic windows (e.g., quetiapine, alfuzosin, astemizole, terfenadine, cisapride, pimozide, quinidine, lurasidone, bepridil, triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5), and ergot alkaloids, particularly, ergotamine, dihydroergotamine, ergonovine, methylergonovine) (see section 4.5).
Sočasna uporaba z zdravili, ki so substrati izooblike CYP3A4 citokroma P450 in imajo ozko terapevtsko okno (npr. kvetiapin, alfuzosin, astemizol, terfenadin, cisaprid, pimozid, kinidin, lurasidon, bepridil, triazolam, peroralne oblike midazolama (za previdnost pri parenteralnih oblikah midazolama glejte poglavje 4.5) in alkaloidi ergot, zlasti ergotamin, dihidroergotamin, ergonovin, metilergonovin) (glejte poglavje 4.5).
Famotidine 40 mg twice daily Atazanavir AUC ↓24% (↓36% ↓11%)* Atazanavir Cmax ↓23% (↓36% ↓8%) * Atazanavir Cmin ↓25% (↓47% ↑7%) *
Atazanavir AUC ↓24% (↓36% ↓11%) * Atazanavir Cmax ↓23% (↓36% ↓8%) * Atazanavir Cmin ↓25% (↓47% ↑7%) *
Due to phenytoin/phenobarbital inducing effect, a reduction in REYATAZ exposure cannot be ruled out.
Zaradi inducirajočega učinka fenitoina/fenobarbitala zmanjšanja izpostavljenosti zdravilu REYATAZ ne moremo izključiti.
Co-administration of REYATAZ with proton pump inhibitors is not recommended (see section 4.5).
Sočasna uporaba zdravila REYATAZ in zaviralcev protonske črpalke ni priporočljiva (glejte poglavje 4.5).
Co-administration of REYATAZ with glecaprevir/pibrentasvir is contraindicated because of the potential increase in the risk of ALT elevations due to a significant increase in glecaprevir and pibrentasvir plasma concentrations (see section 4.3)
Sočasna uporaba zdravila REYATAZ in glecaprevirja/pibrentasvirja je kontraindicirana zaradi možnega večjega tveganja za zvišanje vrednosti ALT, povezanega s pomembnim povečanjem koncentracij glaceprevirja in pibrentasvirja v plazmi (glejte poglavje 4.3).
REYATAZ/ritonavir should not be co-administered with triazolam or orally administered midazolam (see section 4.3), whereas caution should be used with co-administration of REYATAZ/ritonavir and parenteral midazolam.
REYATAZ/ritonavirja se ne sme uporabljati sočasno s triazolamom ali peroralnim midazolamom (glejte poglavje 4.3).
No recommendation regarding dose reduction can be made; therefore, caution should be exercised if REYATAZ is coadministered with clarithromycin.
Če se zdravilo REYATAZ uporablja skupaj s klaritromicinom, je potrebna previdnost.
30 hard capsules: EU/1/03/267/009
Pakiranje v pretisnem omotu: 30 trdih kapsul: EU/1/03/267/009
Adverse reactions were consistent between patients who received REYATAZ 400 mg once daily and patients who received REYATAZ 300 mg with ritonavir 100 mg once daily, except that jaundice and elevated total bilirubin levels were reported more frequently with REYATAZ plus ritonavir.
Pri bolnikih, ki so prejemali zdravilo REYATAZ v odmerku 400 mg enkrat na dan, in bolnikih, ki so prejemali zdravilo REYATAZ v odmerku 300 mg skupaj z ritonavirjem v odmerku 100 mg enkrat na dan, so bili neželeni učinki primerljivi.
Therefore, REYATAZ is contraindicated with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, orally administered midazolam, and ergot alkaloids, particularly ergotamine and dihydroergotamine (see section 4.3).
Zato je kontraindicirana uporaba zdravila REYATAZ z zdravili, ki so substrati za CYP3A4 in imajo ozek terapevtski indeks, npr. kvetiapin, lurasidon, alfuzosin, astemizol, terfenadin, cisaprid, pimozid, kinidin, bepridil, triazolam, peroralne oblike midazolama in alkaloidi ergot, zlasti ergotamin in dihidroergotamin (glejte poglavje 4.3).
REYATAZ/ritonavir, especially when commencing therapy.
REYATAZ/ritonavirjem priporočamo skrben nadzor vrednosti INR, še posebej ob uvedbi zdravljenja.
Atazanavir Cmax ↔5% (↓17% ↑8.4%)* Atazanavir Cmin ↔1.3% (↓10% ↑15)*
Atazanavir AUC ↔2,3% (↓13% ↑10%)* Atazanavir Cmax ↔5% (↓17% ↑8,4%)* Atazanavir Cmin ↔1,3% (↓10% ↑15%) *
NAME OF THE MEDICINAL PRODUCT REYATAZ 200 mg hard capsules atazanavir
IME ZDRAVILA REYATAZ 200 mg trde kapsule atazanavir
REYATAZ 100 mg hard capsules atazanavir
REYATAZ 100 mg trde kapsule atazanavir
Co-administration of REYATAZ/ritonavir and indinavir is not recommended (see section 4.4).
Sočasne uporabe zdravila REYATAZ/ritonavirja in indinavirja se ne priporoča (glejte poglavje 4.4).
Co-administration of alfuzosin with REYATAZ is contraindicated (see section 4.3)
Sočasna uporaba alfuzosina z zdravilom REYATAZ je kontraindicirana (glejte poglavje 4.3).
REYATAZ 200 mg hard capsules atazanavir
REYATAZ 200 mg trde kapsule atazanavir
HCV Protease Inhibitors Boceprevir 800 mg three times daily (atazanavir 300 mg/ritonavir 100 mg once daily)
Zaviralci HCV proteaz Boceprevir 800 mg trikrat na dan (atazanavir
Each capsule contains 300 mg of atazanavir (as sulphate).
Ena kapsula vsebuje 300 mg atazanavirja (v obliki sulfata).
REYATAZ 200 mg hard capsules are also supplied in blister strips in packs of 60 capsules.
REYATAZ 200 mg trde kapsule so na voljo tudi v pretisnih omotih s 60 kapsulami.
Each capsule contains 100 mg of atazanavir (as sulphate).
Ena kapsula vsebuje 100 mg atazanavirja (v obliki sulfata).
The residual mixture is drawn up into the syringe and administered into either the right or left inner cheek of the infant.
Preostalo mešanico izvlecite v brizgo in jo iztisnite otroku v usta v smeri proti desnemu ali levemu licu.
No recommendation regarding dose reduction can be made; therefore, caution should be exercised if
Priporočil za zmanjšanje odmerka ne moremo podati.
the mean baseline CD4 cell count was 344 cells/mm3 (range: 2 to 800 cells/ mm3) and mean baseline plasma HIV-1 RNA was 4.67 log10 copies/ml (range: 3.70 to 5.00 log10 copies/ml).
344 celic/mm3 (območje: 2 do 800 celic/mm3) in povprečna začetna plazemska vrednost HIV-1 RNA 4,67 log10 kopij/ml (območje: 3,70 do 5,00 log10 kopij/ml).
Cholelithiasis has been reported in patients receiving REYATAZ (see section 4.8).
Pri bolnikih, ki so se zdravili z zdravilom REYATAZ, so poročali o pojavu holelitiaze (glejte poglavje 4.8).
REYATAZ 300 mg hard capsules atazanavir
REYATAZ 300 mg trde kapsule atazanavir
NAME OF THE MEDICINAL PRODUCT REYATAZ 300 mg hard capsules atazanavir
IME ZDRAVILA REYATAZ 300 mg trde kapsule atazanavir
Voriconazole 50 mg twice daily (atazanavir 300 mg/ritonavir 100 mg once daily)
Vorikonazol 50 mg dvakrat na dan (atazanavir 300 mg/ritonavir 100 mg enkrat na dan)
NAME OF THE MEDICINAL PRODUCT REYATAZ 100 mg hard capsules atazanavir
IME ZDRAVILA REYATAZ 100 mg trde kapsule atazanavir
ANTIFUNGALS Ketoconazole 200 mg once daily (atazanavir 400 mg once daily)
ZDRAVILA ZA ZDRAVLJENJE GLIVIČNIH OKUŽB Ketokonazol 200 mg enkrat na dan (atazanavir 400 mg enkrat na dan)
The mean baseline CD4 cell count was 214 cells/mm3 (range: 2 to 810 cells/mm3) and mean baseline plasma HIV-1 RNA was 4.94 log10 copies/ml (range: 2.6 to 5.88 log10 copies/ml).
Srednje število celic CD4 v izhodišču je bilo 214 celic/mm3 (razpon od 2 do 810 celic/mm3), srednja vrednost plazemske HIV-1 RNA v izhodišču pa 4,94 log10 kopij/ml (razpon od 2,6 do 5,88 log10 kopij/ml).
For treatment-naive paediatric patients,
Pri predhodno nezdravljenih pediatričnih bolnikih je srednje število celic
b ATV/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose 300 mg/200 mg tablets once daily).
b ATV/RTV skupaj z dizoproksiltenofovirijevim fumaratom/emtricitabinom (fiksni odmerek 300 mg/200 mg tablete enkrat na dan).
Therefore, REYATAZ with ritonavir is contraindicated with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, orally administered midazolam, and ergot alkaloids, particularly ergotamine and dihydroergotamine (see section 4.3).
Zato je kontraindicirana uporaba kombinacije zdravila REYATAZ in ritonavirja z zdravili, ki so substrati za CYP3A4 in imajo ozek terapevtski indeks, npr. kvetiapin, lurasidon, alfuzosin, astemizol, terfenadin, cisaprid, pimozid, kinidin, bepridil, triazolam, peroralne oblike midazolama in alkaloidi ergot, zlasti ergotamin in dihidroergotamin (glejte poglavje 4.3).
Voriconazole 200 mg twice daily (atazanavir 300 mg/ritonavir 100 mg once daily)
Vorikonazol 200 mg dvakrat na dan (atazanavir 300 mg/ritonavir 100 mg enkrat na dan)
REYATAZ 150 mg hard capsules are supplied in bottles of 60 capsules.
REYATAZ 150 mg trde kapsule so na voljo v plastenkah s 60 kapsulami.
Also see PULMONARY ARTERIAL HYPERTENSION in this table for further information regarding coadministration of REYATAZ with sildenafil.
Za nadaljnje informacije o sočasni uporabi zdravila REYATAZ in sildenafila glejte tudi PLJUČNA ARTERIJSKA HIPERTENZIJA v tej preglednici.
Each capsule contains 150 mg of atazanavir (as sulphate).
Ena kapsula vsebuje 150 mg atazanavirja (v obliki sulfata).
Co-administration of REYATAZ/ritonavir with products containing St. John's wort is contraindicated.
Sočasna uporaba zdravila REYATAZ/ritonavirja in pripravkov s šentjanževko je kontraindicirana.
Blister pack:
Pakiranje v plastenki:
Nephrolithiasis has been reported in patients receiving REYATAZ (see section 4.8).
Pri bolnikih, ki so se zdravili z zdravilom REYATAZ, so poročali o pojavu nefrolitiaze (glejte poglavje 4.8).
c Lopinavir/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose 300 mg/200 mg tablets once daily).
c Lopinavir/RTV skupaj z dizoproksiltenofovirijevim fumaratom/emtricitabinom (fiksni odmerek 300 mg/200 mg tablete enkrat na dan).
Co-administration of salmeterol with REYATAZ is not recommended (see section 4.4).
Sočasna uporaba salmeterola in zdravila REYATAZ ni priporočljiva (glejte poglavje 4.4).
ANTIEPILEPTICS
HORMONSKI KONTRACEPTIVI
STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains 200 mg of atazanavir (as sulphate).
NAVEDBA ENE ALI VEČ UČINKOVIN Ena kapsula vsebuje 200 mg atazanavirja (v obliki sulfata).
STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains 100 mg of atazanavir (as sulphate).
NAVEDBA ENE ALI VEČ UČINKOVIN Ena kapsula vsebuje 100 mg atazanavirja (v obliki sulfata).
REYATAZ with ritonavir should be used with caution in patients with mild hepatic impairment.
Pri bolnikih z blago okvaro jeter je treba zdravilo REYATAZ z ritonavirjem uporabljati previdno.
Atazanavir AUC ↑43% (↑30% ↑57%) Atazanavir Cmax ↑12% (↑1% ↑24%) Atazanavir Cmin ↑23% (↑13% ↑134%) Grazoprevir AUC: ↑958% (↑678% Grazoprevir Cmax: ↑524% (↑342% Grazoprevir Cmin: ↑1064% (↑696%
Grazoprevir AUC: ↑958% (↑678% ↑1339%) Grazoprevir Cmax: ↑524% (↑342% ↑781%) Grazoprevir Cmin: ↑1064% (↑696% ↑1602%)
Co-administration of REYATAZ with voxilaprevir-containing regimens is not recommended.
Sočasna uporaba zdravila REYATAZ in zdravil, ki vsebujejo voksilaprevir, ni priporočljiva.
REYATAZ 200 mg hard capsules are supplied in bottles of 60 capsules.
REYATAZ 200 mg trde kapsule so na voljo v plastenkah s 60 kapsulami.